Randall L. Mynatt

Randall L. Mynatt

Auto-generated profile, based on publicly available information

Randall L. Mynatt

Gene Nutrient Interactions Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Obesity Research
Verified
Journal Article
Open access
PDF file
LJLenka Janderová
Lenka Janderová
MMMichele McNeil
Michele McNeil
AMAngela N. Murrell
Angela N. Murrell
RMRandall L. Mynatt
Randall L. Mynatt
SSSteven R. Smith
Steven R. Smith
Objective: To validate the human mesenchymal stem cells (hMSCs) as a new in vitro model for the study of human adipogenesis, to develop the optimal protocol for the differentiation of hMSCs into adipocytes, and to describe effect of mitogen‐activated protein kinase on hMSC differentiation into adipocytes.Research Methods and Procedures: hMSCs, obtained commercially, were differentiated by exposure to insulin, dexamethasone, indomethacin, and 3‐isobutyl‐1‐methylxanthine three times for 3 days each. Various differentiation conditions were examined to optimize differentiation as measured by Oil Red O staining. The gene expression during adipogenic conversion was assessed by reverse‐transcription polymerase chain reaction, real‐time reverse‐transcription polymerase chain reaction, and Western blotting.Results: hMSCs differentiated into adipocytes to a different extent depending on the experimental conditions. We have found that differentiation medium based on medium 199 and containing 170 nM insulin, 0.5 mM 3‐isobutyl‐1‐methylxanthine, 0.2 mM indomethacin, 1 μM dexamethasone, and 5% fetal bovine serum was optimal. However, the replacement of fetal bovine serum with rabbit serum (15%) led to further enhancement of differentiation. Inhibition of mitogen‐activated protein kinase activation also facilitated adipogenic conversion of hMSCs. The pattern of genes expressed during hMSC differentiation into adipocytes (adipsin, peroxisome proliferator‐activated receptor‐γ, CCAAT/enhancer‐binding protein‐β, GLUT4, and leptin) was similar to that observed in other in vitro adipocyte models.Discussion: hMSCs are renewable sources of noncommitted precursors that are able to differentiate into mature adipocytes under the proper hormonal and pharmacological stimuli. Thus, hMSCs represent a new model for the study of human adipogenesis.

20 February 2007 in Diabetologia
Verified
Journal Article
Open access
PDF file
RPR. A. Power
R. A. Power
MHM. W. Hulver
M. W. Hulver
JZJ. Y. Zhang
J. Y. Zhang
JDJ. Dubois
J. Dubois
RMR. M. Marchand
R. M. Marchand
RMR. L. Mynatt
R. L. Mynatt
Aims/hypothesis This study examined the efficacy of supplemental l-carnitine as an adjunctive diabetes therapy in mouse models of metabolic disease. We hypothesised that carnitine would facilitate fatty acid export from tissues in the form of acyl-carnitines, thereby alleviating lipid-induced insulin resistance. Materials and methods Obese mice with genetic or diet-induced forms of insulin resistance were fed rodent chow ± 0.5% l-carnitine for a period of 1–8 weeks. Metabolic outcomes included insulin tolerance tests, indirect calorimetry and mass spectrometry-based profiling of acyl-carnitine esters in tissues and plasma. Results Carnitine supplementation improved insulin-stimulated glucose disposal in genetically diabetic mice and wild-type mice fed a high-fat diet, without altering body weight or food intake. In severely diabetic mice, carnitine supplementation increased average daily respiratory exchange ratio from 0.886 ± 0.01 to 0.914 ± 0.01 (p < 0.01), reflecting a marked increase in systemic carbohydrate oxidation. Similarly, under insulin-stimulated conditions, carbohydrate oxidation was higher and total energy expenditure increased from 172 ± 10 to 210 ± 9 kJ kg fat-free mass−1 h−1 in the carnitine-supplemented compared with control animals. These metabolic improvements corresponded with a 2.3-fold rise in circulating levels of acetyl-carnitine, which accounts for 86 and 88% of the total acyl-carnitine pool in plasma and skeletal muscle, respectively. Carnitine supplementation also increased several medium- and long-chain acyl-carnitine species in both plasma and tissues. Conclusions/interpretation These findings suggest that carnitine supplementation relieves lipid overload and glucose intolerance in obese rodents by enhancing mitochondrial efflux of excess acyl groups from insulin-responsive tissues. Carefully controlled clinical trials should be considered.

1 May 2017 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Closed access
PDF file
JWJaycob D. Warfel
Jaycob D. Warfel
BVBolormaa Vandanmagsar
Bolormaa Vandanmagsar
ODOlga S. Dubuisson
Olga S. Dubuisson
SHSydney M. Hodgeson
Sydney M. Hodgeson
CECarrie M. Elks
Carrie M. Elks
RMRandall L. Mynatt
Randall L. Mynatt
Carnitine palmitoyltransferase 1 (CPT1) is essential for the transport of long-chain fatty acids into the mitochondria for oxidation. Recently, it was reported that decreased CPT1b mRNA in adipose tissue was a contributing factor for obesity in rats. We therefore closely examined the expression level of Cpt1 in adipose tissue from mice, rats, and humans. Cpt1a is the predominate isoform in adipose tissue from all three species. Rat white adipose tissue has a moderate amount of Cpt1b mRNA, but it is very minor compared with Cpt1b expression in muscle. Total CPT1 activity in adipose tissue is also minor relative to other tissues. Both Cpt1a and Cpt1b mRNA were increased in gonadal fat but not inguinal fat by diet-induced obesity in mice. We also measured CPT1a and CPT1b expression in subcutaneous adipose tissue from human subjects with a wide range of body mass indexes (BMIs). Interestingly, CPT1a expression positively correlated with BMI (R = 0.46), but there was no correlation with CPT1b (R = 0.04). Our findings indicate that white adipose tissue fatty acid oxidation capacity is minor compared with that of metabolically active tissues. Furthermore, given the already low abundance of Cpt1b in white adipose tissue, it is unlikely that decreases in its expression can quantitatively decrease whole body energy expenditure enough to contribute to an obese phenotype.

6 August 2009 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
RMRandall L. Mynatt
Randall L. Mynatt

1 April 2001 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
RMRandall L. Mynatt
Randall L. Mynatt
JSJacqueline M. Stephens
Jacqueline M. Stephens
Agouti is a secreted paracrine factor that regulates pigmentation in hair follicle melanocytes. Several dominant mutations cause ectopic expression ofagouti, resulting in a phenotype characterized by yellow fur, adult-onset obesity and diabetes, increased linear growth and skeletal mass, and increased susceptibility to tumors. Humans also produce agouti protein, but the highest levels of agouti in humans are found in adipose tissue. To mimic the human agoutiexpression pattern in mice, transgenic mice (aP2-agouti) that expressagouti in adipose tissue were generated. The transgenic mice develop a mild form of obesity, and they are sensitized to the action of insulin. We correlated the levels of specific regulators of insulin signaling and adipocyte differentiation with these phenotypic changes in adipose tissue. Signal transducers and activators of transcription (STAT)1, STAT3, and peroxisome proliferator-activated receptor (PPAR)-γ protein levels were elevated in the transgenic mice. Treatment of mature 3T3-L1 adipocytes recapitulated these effects. These data demonstrate that agouti has potent effects on adipose tissue. We hypothesize that agouti increases adiposity and promotes insulin sensitivity by acting directly on adipocytes via PPAR-γ.

1 August 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Carrie ElksCarrie Elks
Carrie Elks
PZPeng Zhao
Peng Zhao
RGRyan Grant
Ryan Grant
HHHardy Hang
Hardy Hang
JBJennifer L. Bailey
Jennifer L. Bailey
JSJacqueline M. Stephens
Jacqueline M. Stephens
Oncostatin M (OSM) is a multifunctional gp130 cytokine. Although OSM is produced in adipose tissue, it is not produced by adipocytes. OSM expression is significantly induced in adipose tissue from obese mice and humans. The OSM-specific receptor, OSM receptor β (OSMR), is expressed in adipocytes, but its function remains largely unknown. To better understand the effects of OSM in adipose tissue, we knocked down Osmr expression in adipocytes in vitro using siRNA. In vivo, we generated a mouse line lacking Osmr in adiponectin-expressing cells (OSMRFKO mice). The effects of OSM on gene expression were also assessed in vitro and in vivo. OSM exerts proinflammatory effects on cultured adipocytes that are partially rescued by Osmr knockdown. Osm expression is significantly increased in adipose tissue T cells of high fat-fed mice. In addition, adipocyte Osmr expression is increased following high fat feeding. OSMRFKO mice exhibit increased insulin resistance and adipose tissue inflammation and have increased lean mass, femoral length, and bone volume. Also, OSMRFKO mice exhibit increased expression of Osm, the T cell markers Cd4 and Cd8, and the macrophage markers F4/80 and Cd11c. Interestingly, the same proinflammatory genes induced by OSM in adipocytes are induced in the adipose tissue of the OSMRFKO mouse, suggesting that increased expression of proinflammatory genes in adipose tissue arises both from adipocytes and other cell types. These findings suggest that adipocyte OSMR signaling is involved in the regulation of adipose tissue homeostasis and that, in obesity, OSMR ablation may exacerbate insulin resistance by promoting adipose tissue inflammation.